Loading publications…
The last 5 uploaded publications
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet, Thierry de Baère, Laura Kulik, Philipp K. Haber, Tim F. Greten, Tim Meyer, Riccardo Lencioni (2021). Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology, 18(5), pp. 293-313, DOI: 10.1038/s41575-020-00395-0.
Article145 days agoEvidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
Philipp K. Haber, Marc Puigvehí, Florian Castet, Vennis Lourdusamy, Robert Montal, Parissa Tabrizian, Michael Buckstein, Edward Kim, Augusto Villanueva, Myron Schwartz, Josep M. Llovet (2021). Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020). Gastroenterology, 161(3), pp. 879-898, DOI: 10.1053/j.gastro.2021.06.008.
Article145 days agoInflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi, Florian Castet, Philipp K. Haber, Roser Pinyol, Miguel Torres‐Martín, Laura Torrens, Agavni Mesropian, Huan Wang, Marc Puigvehí, Miho Maeda, Wei Qiang Leow, Elizabeth Harrod, Patricia Taik, Jigjidsuren Chinburen, Erdenebileg Taivanbaatar, Chinbold Enkhbold, M. Solé Arqués, Michael Donovan, Swan N. Thung, Jaclyn Neely, Vincenzo Mazzaferro, Jeffrey Anderson, Sasan Roayaie, Myron Schwartz, Augusto Villanueva, Scott L. Friedman, Andrew Uzilov, Daniela Sia, Josep M. Llovet (2022). Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 72(1), pp. 129-140, DOI: 10.1136/gutjnl-2021-325918.
Article145 days agoImmunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp K. Haber, Miho Maeda, Ugne Balaseviciute, Catherine E. Willoughby, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, Miguel Torres‐Martín, Judit Peix, Daniel Geh, Erik Ramón-Gil, Behnam Saberi, Scott L. Friedman, Derek A. Mann, Daniela Sia, Josep M. Llovet (2021). Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 74(5), pp. 2652-2669, DOI: 10.1002/hep.32023.
Article145 days agoCXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71(10), pp. 2093-2106, DOI: 10.1136/gutjnl-2021-326259.
Article145 days ago